Skip to main content

Retail Clinics

  • Report: FDA warns of long-term PPI use

    SILVER SPRING, Md. — The Food and Drug Administration is warning that long-term use of a class of drugs for gastroesophageal reflux disease may decrease levels of magnesium in the body and increase the risk of such side effects as seizures and heart rhythm problems, according to published reports.

    The reports quoted the FDA as saying that in a quarter of cases of proton-pump inhibitors depleting magnesium from the body, use of magnesium supplements did not bring levels back to normal, and use of the drugs had to be stopped.

  • FDA targets unapproved cough-cold, allergy drugs with Unapproved Drugs Initiative

    SILVER SPRING, Md. — The Food and Drug Administration has taken action against makers of prescription drugs for cough-cold and allergies that don’t have regulatory approval, the agency said Wednesday.

    The action is part of the agency’s Unapproved Drugs Initiative, which seeks to remove from the market drugs that have not received approval. In many cases, the drugs were marketed before the FDA adopted its current regulatory standards.

  • Sugary drinks associated with hypertension, study finds

    DALLAS — A new study published in Hypertension: Journal of the American Heart Association established a link between high blood pressure and the consumption of such beverages as soda and other sugar-sweetened drinks.

  • Cold sore treatment Xerese enters market

    HUDDINGE, Sweden — Meda has launched a new cold sore treatment made by commercialization partner Medivir, Medivir said Tuesday.

    The Swedish drug maker launched Xerese (acyclovir and hydrocortisone), a topical combination product designed to treat recurrent herpes simplex labialis.

    Medivir said the U.S. market for cold sore products is $230 million, and it expected the drug to be successful, given Meda’s presence in the U.S. market.

  • Study: Physicians more likely to prescribe Rxs with adherence incentives

    NEW YORK — Physicians are 30% more likely to prescribe a drug that gives patients incentives to remain adherent to it than they are to prescribe a drug without such a program, according to a new survey.

    The survey of 100 doctors, sponsored by HealthPrize Technologies and conducted by pharmaceutical marketing firm HealthcarePanel.org, also found 89% of doctors were comfortable with the idea of rewarding patients for adherence, along with using education.

  • Cherokee Uniforms accepting nominations for annual Inspired Comfort Award

    LOS ANGELES — Medical scrubs provider Cherokee Uniforms has announced that it is accepting nominations through May 31 for its annual Inspired Comfort Award, which recognizes those healthcare professionals, such as registered nurses and advanced practice nurses, who go above and beyond the call of duty to make a difference for their patients and the communities they serve.

  • Takeda's Edarbi approved as hypertension treatment

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for hypertension, also known as high blood pressure, the agency said Friday.

    The FDA approved Takeda’s Edarbi (azilsartan medoxomil).

  • CVS/pharmacy kicks off 2011 To Your Health program

    WOONSOCKET, R.I. — CVS/pharmacy has announced the launch of the 2011 To Your Health program, offering free preventive health screenings at more than 800 events in communities across the country. The program is designed to help Americans determine their risk for chronic diseases and get them on a path to better health.

    The program will get under way in Houston on March 5, and continue in Dallas, Los Angeles, Washington, D.C., Atlanta, Philadelphia, Chicago and Miami.

X
This ad will auto-close in 10 seconds